Journal of Natural Medicines ( IF 2.5 ) Pub Date : 2021-05-27 , DOI: 10.1007/s11418-021-01525-x Wenfang Li 1 , Xueyan Hu 2 , Yanjie Li 3 , Kedong Song 2
|
Astragalus polysaccharide (APS) has been frequently used as an adjuvant agent responsible for its immunoregulatory activity to enhance efficacy and reduce toxicity of chemotherapy used in the management of breast cancer. However, the other synergism mechanism of APS remains unclear. This study was performed to evaluate the potential targets and possible mechanism behind APS in vivo direct anti-tumor activity on breast cancer. Multiple biological detections were conducted to investigate the protein and mRNA expression levels of key targets. In total, 116 down-regulated and 73 up-regulated differential expressed genes (DEGs) were examined from 7 gene expression datasets. Top ten hub genes were obtained in four typical protein–protein interaction (PPI) network of DEGs involved in each specific biological process (BP, cell cycle, cell proliferation, cell apoptosis and death) that was related to inhibitory activity of APS in vitro against breast cancer cell lines. Four common DEGs (EGFR, ANXA1, KIF14 and IGF1) were further identified in the above four BP-PPI networks, among which EGFR and ANXA1 were the hub genes that were potentially linked to the progression of breast cancer. The results of biological detections indicated that the expression of EGFR in breast cancer cells was down-regulated, while the expression of ANXA1 was markedly increased in response to APS. In conclusion, the present study may provide potential molecular therapeutic targets and a new insight into the mechanism of APS against breast cancer.
Graphic abstract
中文翻译：
黄芪多糖通过调节EGFR和ANXA1对乳腺癌的细胞毒性和生长抑制活性
黄芪多糖 (APS) 经常被用作辅助剂，负责其免疫调节活性，以提高疗效并降低用于治疗乳腺癌的化学疗法的毒性。然而，APS 的其他协同机制尚不清楚。进行这项研究是为了评估 APS 体内直接抗乳腺癌活性背后的潜在靶点和可能的机制。进行了多项生物学检测以研究关键靶标的蛋白质和mRNA表达水平。总共从 7 个基因表达数据集中检查了 116 个下调和 73 个上调的差异表达基因 (DEG)。在参与每个特定生物过程（BP、细胞周期、细胞增殖、细胞凋亡和死亡），这与 APS 在体外对乳腺癌细胞系的抑制活性有关。在上述四个BP-PPI网络中进一步鉴定了四种常见的DEGs（EGFR、ANXA1、KIF14和IGF1），其中EGFR和ANXA1是可能与乳腺癌进展相关的枢纽基因。生物学检测结果表明，乳腺癌细胞中EGFR的表达下调，而ANXA1的表达则响应APS显着升高。总之，本研究可能提供潜在的分子治疗靶点和对 APS 抗乳腺癌机制的新见解。KIF14 和 IGF1) 在上述四个 BP-PPI 网络中被进一步鉴定，其中 EGFR 和 ANXA1 是可能与乳腺癌进展相关的枢纽基因。生物学检测结果表明，乳腺癌细胞中EGFR的表达下调，而ANXA1的表达则响应APS显着升高。总之，本研究可能提供潜在的分子治疗靶点和对 APS 抗乳腺癌机制的新见解。KIF14 和 IGF1) 在上述四个 BP-PPI 网络中被进一步鉴定，其中 EGFR 和 ANXA1 是可能与乳腺癌进展相关的枢纽基因。生物学检测结果表明，乳腺癌细胞中EGFR的表达下调，而ANXA1的表达则响应APS显着升高。总之，本研究可能提供潜在的分子治疗靶点和对 APS 抗乳腺癌机制的新见解。而ANXA1的表达响应APS显着增加。总之，本研究可能提供潜在的分子治疗靶点和对 APS 抗乳腺癌机制的新见解。而ANXA1的表达响应APS显着增加。总之，本研究可能提供潜在的分子治疗靶点和对 APS 抗乳腺癌机制的新见解。
京公网安备 11010802027423号